739 reports of this reaction
4.9% of all EMICIZUMAB reports
#3 most reported adverse reaction
HAEMARTHROSIS is the #3 most commonly reported adverse reaction for EMICIZUMAB, manufactured by Genentech, Inc.. There are 739 FDA adverse event reports linking EMICIZUMAB to HAEMARTHROSIS. This represents approximately 4.9% of all 15,224 adverse event reports for this drug.
Patients taking EMICIZUMAB who experience haemarthrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMARTHROSIS is moderately reported among EMICIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to haemarthrosis, the following adverse reactions have been reported for EMICIZUMAB:
The following drugs have also been linked to haemarthrosis in FDA adverse event reports:
HAEMARTHROSIS has been reported as an adverse event in 739 FDA reports for EMICIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMARTHROSIS accounts for approximately 4.9% of all adverse event reports for EMICIZUMAB, making it one of the most commonly reported side effect.
If you experience haemarthrosis while taking EMICIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.